Vijaya Diagnostic Centre , a prominent player in the healthcare diagnostics sector, has reported a consolidated net profit of 433.00 million rupees for the second quarter. This marks a 3.3% increase from the 419.00 million rupees reported in the same period last year, indicating a steady growth trajectory for the company.

Financial Performance

The company's financial results demonstrate resilience in a competitive healthcare market. Here's a breakdown of the key figures:

Vijaya Diagnostic Centre reported Q2 revenue of 2.02 billion rupees, up from 1.83 billion rupees in the same period last year, representing a 10.4% increase. The company's Q2 EBITDA also saw growth, increasing to 818.00 million rupees from 760.00 million rupees year-over-year. However, the EBITDA margin declined to 40.60% compared to 41.54% in the previous year.

Corporate Developments

In addition to the financial results, Vijaya Diagnostic Centre has made significant corporate moves:

1. Merger Approval: The company has received approval from the National Company Law Tribunal (NCLT) for the amalgamation of Medinova Diagnostic Services Limited with Vijaya Diagnostic Centre Limited.

2. Effective Date: The merger scheme became effective on November 4, following the filing of the NCLT order with the Registrar of Companies, Hyderabad.

3. Share Exchange Ratio: As part of the merger, shareholders of Medinova Diagnostic Services will receive 1 equity share of Vijaya Diagnostic Centre for every 22 shares held in Medinova.

4. Record Date: November 25 has been set as the record date for determining the shareholders of Medinova who will be eligible for shares in Vijaya Diagnostic Centre.

5. Capital Structure Changes: Post-merger, Vijaya Diagnostic Centre's authorized share capital has increased to ₹230.50 million, divided into 230.50 million equity shares of ₹1 each.

6. Subsidiary Acquisition: As a result of the merger, Medinova Millennium MRI Services LLP, previously a wholly-owned subsidiary of Medinova Diagnostic Services, has now become a wholly-owned subsidiary of Vijaya Diagnostic Centre.

Market Implications

The increase in revenue and net profit, coupled with the strategic merger, positions Vijaya Diagnostic Centre for potential growth in the diagnostic services market. The company's ability to grow its top line and maintain profitability, despite a slight decline in EBITDA margin, demonstrates its resilience in a competitive landscape.

The integration of Medinova Diagnostic Services and the resulting expansion of Vijaya's subsidiary portfolio could potentially lead to enhanced market reach and operational efficiencies.

As the healthcare diagnostics sector continues to evolve, Vijaya Diagnostic Centre's latest financial results and corporate restructuring may signal its readiness to capitalize on emerging opportunities in the industry.

Vijaya Diagnostic Centre Limited (VDCL) has recently made two significant announcements that could impact its organizational structure and market position.

Leadership Change

Mr. Srinivas Lanka, the Chief Technology Officer (CTO) of Vijaya Diagnostic Centre Limited, has tendered his resignation. According to the company's disclosure:

The company has expressed its appreciation for Mr. Lanka's services and contributions during his tenure.

Corporate Restructuring

In a separate development, Vijaya Diagnostic Centre Limited has received the certified true copy of an order from the National Company Law Tribunal (NCLT), Hyderabad, dated October 13, 2025. This order approves the scheme of amalgamation between VDCL and Medinova Diagnostic Services Limited (MDSL).

Key points regarding the merger:

The merger will become effective when both companies file the certified true copy of the NCLT order, along with the certified true copy of the Scheme of Amalgamation, with the Registrar of Companies in Hyderabad.

Implications and Next Steps

1. Leadership Transition: With the CTO's departure, VDCL may need to initiate a search for a new technology leader to maintain its technological edge in the diagnostic sector.

2. Merger Process: The company will need to complete the necessary filings with the Registrar of Companies to make the merger effective.

3. Shareholder Impact: VDCL will announce a record date for allocating shares to MDSL shareholders as part of the amalgamation process.

4. Market Position: The merger with Medinova Diagnostic Services Limited could potentially strengthen Vijaya Diagnostic Centre's market position in the diagnostic services industry.

Investors and stakeholders of both Vijaya Diagnostic Centre Limited and Medinova Diagnostic Services Limited should keep an eye out for further announcements regarding the effective date of the merger and the share allotment process.